چكيده لاتين :
The administration of b-interferon is a recognized treatment for multiple
sclerosis. The frequency of side effects is an important factor in drug or product
selection. In this study, the side effects of three available b-interferon products are
compared in 122 multiple sclerosis patients who were treated with b-interferon
products for at least three months and had the Expanded Disability Status Scale
(EDSS) between 1 and 6. The frequencies of side effects were determined for each
group and the collected information were compared in the three treated groups. Fever,
chills, headache, malaise and asthenia were the most frequent observed complications.
Necrosis at the injection site was seen only in Betaseron group. Somnolence was
more frequent with the administration of Avonex. Gastro-intestinal disturbances were
less frequent in patients treated with Rebif. Weight gain was more frequent in
patients treated with Avonex, and seizure and migraine were observed only in this
group.Urticaria and hypersensitivity skin reactions were less frequent with the
administration of Avonex. Rebif may be a better choice for patients with gastrointestinal
disturbances, suicidal attempts and chronic fatigue syndrome. Avonex may
be better tolerated in patients with a history of urticaria and hypersensitivity skin
reactions, but it is less recommended for patients with a history of seizure, migraine
and syncope. Betaseron may be a better choice in patients with a history of chest
pain and hypertension.
